Cytomegalovirus vaccine - AlphaVax/GlaxoSmithKline

Drug Profile

Cytomegalovirus vaccine - AlphaVax/GlaxoSmithKline

Alternative Names: AVX 601

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AlphaVax
  • Class Antivirals; Cytomegalovirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cytomegalovirus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cytomegalovirus infections(Prevention, In volunteers) in USA (IM, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cytomegalovirus infections(Prevention, In volunteers) in USA (SC, Injection)
  • 02 Mar 2015 GlaxoSmithKline acquires Novartis' global vaccine business (excluding influenza vaccines)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top